ArticleThe Journal of allergy and clinical immunology2026
B-cell lymphocytosis and reprogramming due to biallelic CARD11 mutations.
Article in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deleterious germline CARD11 gain-of-function variants alter human B-cell and CD4+ T-cell differentiation and function.Clinical and experimental immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAdaptive immune responses are tightly controlled by proteins including CARD11 that regulate signaling events downstream of the T- and B-cell receptors. Germline mutations in CARD11 cause several distinct monogenic inborn errors of immunity with early childhood onset and potentially fatal prognoses. Somatic CARD11 gain-of-function mutations are associated with B-cell malignancies. Precisely how various CARD11 mutations culminate in unique clinical entities, and the mechanisms of CARD11-driven B-cell proliferation, is not fully understood.
objectiveWe sought to identify the genetic basis of disease and characterize immune-cell phenotypes and functions in a patient with apparent BENTA (B-cell expansion with nuclear factor-κB [NF-κB] and T-cell anergy) disease and a history of sibling death in early childhood.
methodsWe used whole-exome sequencing, flow and mass cytometry, whole blood mRNA analyses, in vitro T-cell proliferation and B-cell differentiation assays, and single-cell RNA sequencing of patient-derived samples to identify the genetic basis of disease and define its molecular and cellular mechanisms. We also ectopically expressed wild-type and mutant forms of CARD11 in T and B cells and assessed their functional impacts on NF-κB-dependent responses.
resultsWe report a surprising new genetic basis of BENTA caused by homozygosity for the novel CARD11 mutation R331P and characterized by massive expansion of B cells with a naive surface phenotype and aberrant transcriptional program. This autosomal-recessive form of BENTA features exaggerated B-cell lymphocytosis relative to monoallelic BENTA. Furthermore, we have identified patterns of gene expression that distinguish B cells of patients with the autosomal-recessive form of BENTA from those of healthy controls and from monoallelic BENTA. We found that ectopic CARD11 R331P expression induced constitutive NF-κB activity in T and B cells. These data suggest that R331P is a gain-of-function mutation and causes BENTA in homozygosity.
conclusionsThese results define a novel autosomal-recessive form of BENTA disease. Additional analysis of mutation-driven changes in B-cell function may shed light on the mechanisms of B lymphomagenesis in patients with germline or somatic CARD11 variants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.